Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study
- PMID: 32554440
- PMCID: PMC10231559
- DOI: 10.1136/ebmental-2020-300149
Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study
Abstract
Introduction: Clinical guidelines recommend antidepressants as the first line of treatment for adults with moderate-to-severe depression. Randomised trials provide the best evidence on the comparative effectiveness of antidepressants for depression, but are limited by a short follow-up and a highly selected population. We aim to conduct a cohort study on a large database to assess acceptability, efficacy, safety and tolerability of antidepressant monotherapy in people with depressive disorder in primary care.
Methods and analysis: This is a protocol for a cohort study using data from the QResearch primary care research database, which is the largest general practice research database in the UK. We will include patients registered for at least 1 year from 1 January 1998, diagnosed with a new episode of depression and on antidepressant and a comparison group not on antidepressant. The exposure of interest will be treatment with antidepressant medications. Our outcomes will be acceptability (treatment discontinuation due to any cause), efficacy (clinical response and remission); safety (adverse events (AEs) and all-cause mortality); and tolerability (dropouts due to any AE) measured at 2 months, 6 months and 1 year. For each outcome, we will estimate the absolute risks for all antidepressants, and relative effects between antidepressants using Cox's proportion hazards models. We will calculate HRs and 99.9% CIs for each outcome of interest.
Discussion: The main limitation is the observational nature of our study, while the major strengths include the large representative population contained in QResearch and the possibly high generalisability.
Keywords: adult psychiatry; depression & mood disorders.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: AC has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials) and Angelini Pharma. He has also organised a workshop about digital mental health sponsored by Angelini Pharma.
References
-
- James SL, Abate D, Abate KH, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1789–858. 10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed
-
- Kennedy SH, Lam RW, McIntyre RS, et al. . Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry 2016;61:540–60. 10.1177/0706743716659417 - DOI - PMC - PubMed
-
- National Institute for Health and Care Excellence . Depression in adults: recognition and management. London, UK: NICE, 2009. Available: https://www.nice.org.uk/guidance/cg90 [Accessed 2 Feb 2020]. - PubMed